Efficacy and safety of long-term saxagliptin monotherapy and add-on therapy in Japanese patients with type 2 diabetes

Japanese Pharmacology and Therapeutics

Volumn 42, Issue 7, 2014, Pages 519-534

  Seino, Yutaka ^a  

^a KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

Long term combination study; Long term monotherapy study; Saxagliptin; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; SAXAGLIPTIN; SULFONYLUREA; TIAZOLIDINEDIONE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; JAPANESE (PEOPLE); LONG TERM CARE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 3 CLINICAL TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84906221470     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. http://www.mhlw.go.jp/bunya/kenkou/eiyou/h24-houkoku.html
2. 1, Darsow T, Maggs DG. Incretin-based therapie. J Diabetes 2012; 4 : 55-67.
3. Van Gaal LE, Gtukin SW, Nauck MA. Exploiting the anidiabetic properties of incretins to treat type 2 diabetes mellitus : glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol 2008; 158 : 773-84. (Pubitemid 351837365)
4. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, et al. International clinical harmonization of glycated hemoglobin in Japan : From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int 2012; 3 : 8-10.
5. Kirby M, Yu DM, O'Connor S, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) 2009; 118 : 31-41.
6. Wang A, Dorso C, Kopcho L, Locke R, Langish R, Harstad E, et al. Potency, selectivity and prolonged binding of saxagliptin to DPP4 : maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating inhibitor. BMC Pharmacol 2012; 12 : 2.
7. Stenlöf K, Raz I, Neutel J, Ravichandram S, Berglind N, Chen R. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin 2010; 26 : 2355-63.
8. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, Chen R. Effect of saxagliptin monotherapy in treatment - naïve patients with type 2 diabetes. Curr Med Res Opin 2009; 25 : 2401-11.
9. Frederich R, McNeil R, Berglind N, Fleming D, Chen R. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment - naïve patients with type 2 diabetes mellitus : a randomized controlled trial. Diabetol Metab Syndr 2012; 4 : 36-47.
10. DeFonzo, RA, Hissa MN, Garber AJ, Gross JL, Yuyan R, Ravichandran S, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32 : 1649-55.
11. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes; a randomized controlled trial. Int J Clin Pract 2009; 63 : 1395-406.
12. Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009; 94 : 4810-9.
13. Goke, B, Gallwitz B, Eriksson J, Hellqvist Å, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone : a 52-week randomized controlled trial. Int J Clin Pract 2010; 64 : 1619-31.
14. Gautier JF, Sauvanet JP. Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program : predictive factor of the treatment response in type 2 diabetes. Ann Endocrinol (Paris) 2011; 72 : 287-95.
15. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med 2013; 369 : 1317-26.
16. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012; 28 : 513-23.
17. Itamar Raz. Results from SAVOR. EASD in Barcelona, 2013.
18. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356 : 2457-71. (Pubitemid 46919772)
19. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. Rosiglitazone evaluated for cardiovascular outcomes - An Interim analysis. N Engl J Med 2007; 357 : 28-38. (Pubitemid 47026732)
20. Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I. Saxagliptin improves glycaemic control and its well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011; 13 : 523-32.
21. Doouchet J, Chacra A, Maheux P, Lu J, Harris S, Rosenstock J. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011; 27 : 863-9.